Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Preferred Stock Liabilities (2023)

CG Oncology (CGON) has disclosed Preferred Stock Liabilities for 1 consecutive years, with $10.0 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Preferred Stock Liabilities changed N/A year-over-year to $10.0 million, compared with a TTM value of $10.0 million through Dec 2023, changed N/A, and an annual FY2023 reading of $10.0 million, changed N/A over the prior year.
  • Preferred Stock Liabilities was $10.0 million for Q4 2023 at CG Oncology, down from $22.0 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $47.3 million in Q1 2023 and bottomed at $3.6 million in Q2 2023.